Table 3.

The most common TEAEs reported from Week 24 to Week 104.

N (%)	All 150 mg	All 110 to 150 mg	All patients
n	9	8	17
Nasopharyngitis	2 (22.2)	1 (12.5)	3 (17.6)
Abdominal pain	1 (11.1)	1 (12.5)	2 (11.8)
Cystitis	1 (11.1)	1 (12.5)	2 (11.8)
Influenza	0	2 (25.0)	2 (11.8)
Vertigo	1 (11.1)	1 (12.5)	2 (11.8)

The most common TEAEs are those that occurred in at least 10% of patients who entered Part 2 of APeX-J (n = 17).

Abbreviation: TEAE, treatment-emergent adverse event